Austin, Texas — Breyer Capital, a global investment firm known for backing high-impact entrepreneurs, has named Morgan Cheatham as Partner and Head of Healthcare and Life Sciences. In his new role, Cheatham will lead the firm’s early-stage investments in healthcare and life sciences, with a focus on breakthrough biomedical technologies and innovative care models. He will work closely with founder Jim Breyer and the firm’s portfolio of healthcare companies, which includes OpenEvidence, Artera, Arena Bioworks, Atropos Health, Cleerly, Iterative Health, Slope, and SandboxAQ.
Cheatham joins Breyer Capital from Bessemer Venture Partners, where he served as Vice President, focusing on healthcare and life sciences investments across software, therapeutics, diagnostics, and services. During his time at Bessemer, he led the firm’s healthcare AI investment thesis and sourced more than a dozen early-stage deals. Among these were major investments in Abridge and Hinge Health, both of which have since grown into multi-billion-dollar companies, along with rapidly scaling firms such as Plenful and Turquoise Health.
Cheatham also played a pivotal role in Bessemer’s biotech practice, partnering with companies like Seismic Therapeutics and co-founding Decoding Bio, a digital platform that explores the intersection of artificial intelligence and biotechnology. In addition to his investment credentials, Cheatham is a physician by training. He continues to serve as a Clinical Fellow in Genomics at Harvard and is a member of the editorial team at NEJM AI. His achievements earned him a spot on Forbes’ 30 Under 30 list for Venture Capital in 2023.
“We are thrilled to welcome Morgan to Breyer Capital,” said Jim Breyer, founder of the firm. “He brings a strong track record in healthcare and life sciences investing, deep sector expertise, and a powerful network of innovators. Morgan shares our passion for advancing technologies that improve lives – whether through breakthroughs in biomedical science or new models of care that transform patient access and experience. We’re excited about the impact he’ll have on our portfolio and the broader healthcare ecosystem.”
Cheatham highlighted the rapid pace of innovation in the healthcare sector as a key driver for his move. “Scientific and technological progress is outpacing the evolution of healthcare delivery,” he said. “The next generation of healthcare and life sciences will emerge from the convergence of breakthrough discoveries, urgent clinical needs, and meaningful institutional change. I look forward to building on Breyer Capital’s strong track record of supporting visionary founders at this intersection, and to invest in teams that are reimagining healthcare to address the most pressing challenges of our time.”
